NeuroSense Gross Profit vs Research Development Analysis

NRSNW Stock

USD 0.24 0.06 20.00%

NeuroSense Therapeutics financial indicator trend analysis is infinitely more than just investigating NeuroSense Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NeuroSense Therapeutics is a good investment. Please check the relationship between NeuroSense Therapeutics Gross Profit and its Research Development accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuroSense Therapeutics Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy NeuroSense Stock please use our How to Invest in NeuroSense Therapeutics guide.

Gross Profit vs Research Development

Gross Profit vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NeuroSense Therapeutics Gross Profit account and Research Development. At this time, the significance of the direction appears to have pay attention.

The correlation between NeuroSense Therapeutics' Gross Profit and Research Development is -0.92. Overlapping area represents the amount of variation of Gross Profit that can explain the historical movement of Research Development in the same time period over historical financial statements of NeuroSense Therapeutics Ltd, assuming nothing else is changed. The correlation between historical values of NeuroSense Therapeutics' Gross Profit and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Gross Profit of NeuroSense Therapeutics Ltd are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Gross Profit i.e., NeuroSense Therapeutics' Gross Profit and Research Development go up and down completely randomly.

Correlation Coefficient

-0.92

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Gross Profit

Gross profit is a required income statement account that reflects total revenue of NeuroSense Therapeutics Ltd minus its cost of goods sold. It is profit before NeuroSense Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Research Development

Most indicators from NeuroSense Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NeuroSense Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuroSense Therapeutics Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy NeuroSense Stock please use our How to Invest in NeuroSense Therapeutics guide.Enterprise Value is likely to climb to about 12.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 3.3 M in 2024.

NeuroSense Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital	Common Stock	Short Long Term Debt Total	Short Term Debt
Total Assets		0.55	0.46	0.74	0.5	-0.95	-0.52	0.33	0.95	0.42	-0.84	1.0	0.87	0.44	-0.51	0.95	0.72	0.6	0.74	0.5	1.0	0.85	-0.25	-0.46	0.24
Other Current Liab	0.55		0.99	-0.14	0.82	-0.39	-1.0	0.97	0.43	0.79	-0.89	0.52	0.82	0.97	-0.93	0.75	0.9	0.98	-0.14	0.83	0.53	0.03	-0.85	-0.95	0.86
Total Current Liabilities	0.46	0.99		-0.24	0.79	-0.3	-0.99	0.99	0.35	0.77	-0.84	0.43	0.76	0.97	-0.92	0.67	0.86	0.97	-0.24	0.81	0.44	-0.07	-0.89	-0.95	0.9
Total Stockholder Equity	0.74	-0.14	-0.24		0.06	-0.77	0.15	-0.38	0.72	-0.01	-0.3	0.75	0.4	-0.21	0.07	0.55	0.2	-0.09	1.0	0.04	0.75	0.98	0.46	0.16	-0.47
Property Plant And Equipment Net	0.5	0.82	0.79	0.06		-0.27	-0.85	0.72	0.25	1.0	-0.8	0.46	0.72	0.89	-0.96	0.74	0.91	0.72	0.06	1.0	0.48	0.14	-0.45	-0.93	0.47
Net Debt	-0.95	-0.39	-0.3	-0.77	-0.27		0.36	-0.19	-0.99	-0.17	0.73	-0.95	-0.81	-0.22	0.27	-0.84	-0.58	-0.49	-0.77	-0.27	-0.95	-0.89	0.13	0.23	-0.13
Retained Earnings	-0.52	-1.0	-0.99	0.15	-0.85	0.36		-0.96	-0.39	-0.83	0.88	-0.49	-0.81	-0.98	0.95	-0.74	-0.91	-0.97	0.15	-0.87	-0.51	-0.02	0.82	0.97	-0.84
Accounts Payable	0.33	0.97	0.99	-0.38	0.72	-0.19	-0.96		0.24	0.72	-0.76	0.3	0.67	0.95	-0.87	0.56	0.78	0.95	-0.38	0.75	0.31	-0.21	-0.92	-0.92	0.93
Cash	0.95	0.43	0.35	0.72	0.25	-0.99	-0.39	0.24		0.16	-0.74	0.95	0.82	0.26	-0.29	0.84	0.58	0.54	0.72	0.26	0.95	0.85	-0.22	-0.26	0.22
Non Current Assets Total	0.42	0.79	0.77	-0.01	1.0	-0.17	-0.83	0.72	0.16		-0.74	0.38	0.65	0.88	-0.95	0.67	0.87	0.68	-0.01	0.99	0.39	0.06	-0.44	-0.92	0.46
Non Currrent Assets Other	-0.84	-0.89	-0.84	-0.3	-0.8	0.73	0.88	-0.76	-0.74	-0.74		-0.82	-0.97	-0.82	0.84	-0.96	-0.95	-0.91	-0.3	-0.81	-0.83	-0.46	0.6	0.83	-0.61
Cash And Short Term Investments	1.0	0.52	0.43	0.75	0.46	-0.95	-0.49	0.3	0.95	0.38	-0.82		0.86	0.4	-0.47	0.93	0.69	0.57	0.75	0.46	1.0	0.86	-0.23	-0.43	0.22
Net Receivables	0.87	0.82	0.76	0.4	0.72	-0.81	-0.81	0.67	0.82	0.65	-0.97	0.86		0.71	-0.74	0.97	0.94	0.86	0.4	0.73	0.86	0.56	-0.5	-0.72	0.51
Common Stock Shares Outstanding	0.44	0.97	0.97	-0.21	0.89	-0.22	-0.98	0.95	0.26	0.88	-0.82	0.4	0.71		-0.98	0.67	0.87	0.91	-0.21	0.9	0.42	-0.08	-0.81	-1.0	0.82
Inventory	-0.51	-0.93	-0.92	0.07	-0.96	0.27	0.95	-0.87	-0.29	-0.95	0.84	-0.47	-0.74	-0.98		-0.74	-0.91	-0.85	0.07	-0.96	-0.48	-0.04	0.69	0.99	-0.7
Other Current Assets	0.95	0.75	0.67	0.55	0.74	-0.84	-0.74	0.56	0.84	0.67	-0.96	0.93	0.97	0.67	-0.74		0.91	0.77	0.55	0.74	0.94	0.68	-0.39	-0.7	0.4
Other Stockholder Equity	0.72	0.9	0.86	0.2	0.91	-0.58	-0.91	0.78	0.58	0.87	-0.95	0.69	0.94	0.87	-0.91	0.91		0.88	0.2	0.92	0.7	0.34	-0.54	-0.89	0.56
Total Liab	0.6	0.98	0.97	-0.09	0.72	-0.49	-0.97	0.95	0.54	0.68	-0.91	0.57	0.86	0.91	-0.85	0.77	0.88		-0.09	0.74	0.59	0.1	-0.86	-0.88	0.87
Net Invested Capital	0.74	-0.14	-0.24	1.0	0.06	-0.77	0.15	-0.38	0.72	-0.01	-0.3	0.75	0.4	-0.21	0.07	0.55	0.2	-0.09		0.04	0.75	0.98	0.46	0.16	-0.47
Property Plant And Equipment Gross	0.5	0.83	0.81	0.04	1.0	-0.27	-0.87	0.75	0.26	0.99	-0.81	0.46	0.73	0.9	-0.96	0.74	0.92	0.74	0.04		0.47	0.12	-0.47	-0.93	0.49
Total Current Assets	1.0	0.53	0.44	0.75	0.48	-0.95	-0.51	0.31	0.95	0.39	-0.83	1.0	0.86	0.42	-0.48	0.94	0.7	0.59	0.75	0.47		0.86	-0.24	-0.44	0.23
Net Working Capital	0.85	0.03	-0.07	0.98	0.14	-0.89	-0.02	-0.21	0.85	0.06	-0.46	0.86	0.56	-0.08	-0.04	0.68	0.34	0.1	0.98	0.12	0.86		0.29	0.03	-0.29
Common Stock	-0.25	-0.85	-0.89	0.46	-0.45	0.13	0.82	-0.92	-0.22	-0.44	0.6	-0.23	-0.5	-0.81	0.69	-0.39	-0.54	-0.86	0.46	-0.47	-0.24	0.29		0.75	-1.0
Short Long Term Debt Total	-0.46	-0.95	-0.95	0.16	-0.93	0.23	0.97	-0.92	-0.26	-0.92	0.83	-0.43	-0.72	-1.0	0.99	-0.7	-0.89	-0.88	0.16	-0.93	-0.44	0.03	0.75		-0.76
Short Term Debt	0.24	0.86	0.9	-0.47	0.47	-0.13	-0.84	0.93	0.22	0.46	-0.61	0.22	0.51	0.82	-0.7	0.4	0.56	0.87	-0.47	0.49	0.23	-0.29	-1.0	-0.76

Click cells to compare fundamentals

NeuroSense Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for NeuroSense Stock Analysis

When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NeuroSense Gross Profit vs Research Development Analysis

Gross Profit vs Research Development

Gross Profit vs Research Development Correlation Analysis

Correlation Coefficient

Gross Profit

Research Development

NeuroSense Therapeutics fundamental ratios Correlations

NeuroSense Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for NeuroSense Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments

Short Term Debt	- 1.0	Common Stock
Short Long Term Debt Total	- 1.0	Common Stock Shares Outstanding
Retained Earnings	- 1.0	Other Current Liab
Cash	- 0.99	Net Debt
Retained Earnings	- 0.99	Total Current Liabilities
Inventory	- 0.98	Common Stock Shares Outstanding